passages: 852
passages: document
passages: A selective angiotensin receptor antagonist , Valsartan , produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness . We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on left ventricular hypertrophy ( LVH ) in patients on continuous ambulatory peritoneal dialysis ( CAPD ) . In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) . The target blood pressure ( BP ) was 140/90 mmHg or lower in both groups . The following parameters were measured before and at the end of the study : aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography . Periodically recorded were body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance . Two-way analysis of variance for repeated measurements was used for statistical analysis . Systolic and diastolic BP were both reduced in patients treated with ARB . The LVMi was significantly reduced in patients treated with ARB ( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving placebo ( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) . The decrease in LVMi was associated with a reduction in PWV and AI . In CAPD patients with LVH , ARB reduced LVMi in association with alterations in arterial hemodynamics .
entities: 853
entities: Intervention_Pharmacological
entities: Valsartan
entities: 854
entities: Intervention_Pharmacological
entities: selective angiotensin II receptor blocker ( ARB )
entities: 855
entities: Intervention_Pharmacological
entities: ARB valsartan
entities: 856
entities: Intervention_Control
entities: placebo
entities: 857
entities: Intervention_Pharmacological
entities: ARB .
entities: 858
entities: Intervention_Pharmacological
entities: ARB
entities: 859
entities: Intervention_Control
entities: placebo
entities: 860
entities: Intervention_Pharmacological
entities: ARB
entities: 861
entities: Outcome_Physical
entities: blood pressure ( BP )
entities: 862
entities: Outcome_Physical
entities: aortic and large-artery compliance
entities: 863
entities: Outcome_Physical
entities: arterial wave reflections [ pulse wave velocity ( PWV )
entities: 864
entities: Outcome_Physical
entities: augmentation index ( AI ) application tonometry ]
entities: 865
entities: Outcome_Physical
entities: cardiac echocardiography .
entities: 866
entities: Outcome_Physical
entities: body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .
entities: 867
entities: Outcome_Physical
entities: Systolic and diastolic BP
entities: 868
entities: Outcome_Physical
entities: LVMi
entities: 869
entities: Outcome_Physical
entities: LVMi
entities: 870
entities: Outcome_Physical
entities: PWV
entities: 871
entities: Outcome_Physical
entities: AI
entities: 872
entities: Outcome_Physical
entities: LVMi
entities: 873
entities: Participant_Condition
entities: left ventricular hypertrophy
entities: 874
entities: Participant_Condition
entities: patients on continuous ambulatory peritoneal dialysis ( CAPD ) .
entities: 875
entities: Participant_Sample-size
entities: 24
entities: 876
entities: Participant_Condition
entities: CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women
entities: 877
entities: Participant_Condition
entities: LVMi > 137 g/m2 for men